Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study

Table 1 Treatment Schedule

Group	Visit (Week)
Group	Baseline	1	4	8	12	16	20	24	28	32	36
Treatment group (sirolimus + aflibercept)	S	A	S	A	S	A	S	A^a	S	A^a	Final Exam
Control group (aflibercept monotherapy)	A	SH	SH	A	SH	A	SH	A^a	SH	A^a	Final Exam

The treatment group was treated with sirolimus (S) and adjunct aflibercept (A). The control group received aflibercept (A) or a sham (SH) treatment
^aIndicates that treatment is at the discretion of the investigator based on meeting adequate anatomical and visual acuity benchmarks

ISSN: 2056-9920